中国临床药学杂志

参考文献

[1] YAO H Q, ZHANG A Q, LI D L, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes:systematic review and network meta-analysis[J]. BMJ, 2024, 384:e076410.

[2] DING Y N, SHI Y F, GUAN R F, et al. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus:a Bayesian network meta-analysis[J].Pharmacol Res, 2024, 199:107031.

[3]梁静茹,杨晓蕾,杜婉笛,等.新型GLP-1受体激动剂司美格鲁肽的临床研究进展[J].中国临床药学杂志, 2022, 31(10):790.

[4]中华医学会内分泌学分会,中华医学会糖尿病学分会.胰高糖素样肽-1(GLP-1)受体激动剂用于治疗2型糖尿病的临床专家共识[J].中华内科杂志, 2020, 59(11):836.

[5]俞恬,刘少华,魏安华,等.胰高血糖素样肽1受体激动剂治疗合并超重或肥胖的2型糖尿病的疗效和安全性的Meta分析[J].药物流行病学杂志, 2024, 33(5):519.

[6] OVERGAARD R V, HERTZ C L, INGWERSEN S H, et al. Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes[J]. Cell Rep Med,2021, 2(9):100387.

[7] JONES A G, MCDONALD T J, SHIELDS B M, et al. Markers ofβ-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes[J]. Diabetes Care, 2016,39(2):250.

[8] ZHANG Z Q, ZHANG Q L, TAN Y, et al. GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal:a system review and network meta-analysis[J]. Front Endocrinol, 2023,14:1149328.

[9] YU M J, WANG K Y, LIU H M, et al. GLP1R variant is associated with response to exenatide in overweight Chinese Type 2 diabetes patients[J]. Pharmacogenomics, 2019, 20(4):273.

[10] LONG J C, LIU Y J, DUAN Y Q, et al. Effect of GLP-1R rs2254336 and rs3765467 polymorphisms on gastrointestinal adverse reactions in type 2 diabetes patients treated with liraglutide[J]. Eur J Clin Pharmacol, 2022, 78(4):589.

[11] DAWED A Y, MARI A, BROWN A, et al. Pharmacogenomics of GLP-1 receptor agonists:a genome-wide analysis of observational data and large randomised controlled trials[J]. Lancet Diabetes Endocrinol, 2023, 11(1):33.

[12] LI W Z, LI P Z, LI R, et al. GLP1R single-nucleotide polymorphisms rs3765467 and rs10305492 affect β cell insulin secretory capacity and apoptosis through GLP-1[J]. DNA Cell Biol, 2020, 39(9):1700.

[13] LIN C H, LEE Y S, HUANG Y Y, et al. Polymorphisms of GLP-1 receptor gene and response to GLP-1 analogue in patients with poorly controlled type 2 diabetes[J]. J Diabetes Res, 2015,2015:176949.

[14] SATHANANTHAN A, MAN C D, MICHELETTO F, et al.Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects:a pilot study[J]. Diabetes Care, 2010, 33(9):2074.

[15] CHEDID V, VIJAYVARGIYA P, CARLSON P, et al. Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying:a pilot pharmacogenetics study[J]. Neurogastroenterol Motil, 2018,30(7):e13313.

[16] FERREIRA M C, DA SILVA M E R, FUKUI R T, et al. Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes[J]. Diabetol Metab Syndr, 2019, 11:10.

[17]周丽明,许雯,颜雪梅,等. SORCS1rs1416406基因多态性与艾塞那肽疗效的相关性[J].中华医学杂志, 2017, 97(18):1415.

[18] PEREIRA M J, LUNDKVIST P, KAMBLE P G, et al. A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes:metabolic effects and markers associated with bodyweight loss[J]. Diabetes Ther, 2018, 9(4):1511.

[19] GENG Z X, LI Q, HUANG R, et al. KCNQ1 variant rs163184 is a potential biomarker of glycemic response to exenatide[J].Pharmacogenomics, 2022, 23(6):355.

[20] GRANT S F, THORLEIFSSON G, REYNISDOTTIR I, et al.Variant of transcription factor 7-like 2(TCF7L2)gene confers risk of type 2 diabetes[J]. Nat Genet, 2006, 38(3):320.

[21] VILLAREAL D T, ROBERTSON H, BELL G I, et al. TCF7L2variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action[J]. Diabetes, 2010, 59(2):479.

[22] CROPANO C, SANTORO N, GROOP L, et al. The rs7903146variant in the TCF7L2 gene increases the risk of prediabetes/type2 diabetes in obese adolescents by impairing β-cell function and hepatic insulin sensitivity[J]. Diabetes Care, 2017, 40(8):1082.

[23] KUMAR S, PRAKASH P, KUMARI R, et al. Genetic association of transcription factor 7-like-2 rs7903146 polymorphism with type2 diabetes mellitus[J]. Cureus, 2024, 16(1):e52709.

[24] YAU B, BLOOD Z, AN Y S, et al. Type 2 diabetes-associated s i n g l e n u c l e o t i d e p o l y m o r p h i s m i n S o r c s 1 g e n e r e s u l t s i n alternative processing of the Sorcs1 protein in INS1 β-cells[J].Sci Rep, 2019, 9(1):19466.

[25] CHENG S, WU Y L, WU W L, et al. Association of rs734312 and rs10010131 polymorphisms in WFS1 gene with type 2 diabetes mellitus:a meta-analysis[J]. Endocr J, 2013, 60(4):441.

[26] YU X X, LIAO M Q, ZENG Y F, et al. Associations of KCNQ1polymorphisms with the risk of type 2 diabetes mellitus:an updated meta-analysis with trial sequential analysis[J]. J Diabetes Res,2020, 2020:7145139.

[27] DE LUIS D A, DIAZ SOTO G, IZAOLA O, et al. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor[J]. J Diabetes Complications, 2015, 29(4):595.

[28] JENSTERLE M, PIR?B, GORI?AR K, et al. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS:a pilot study[J]. Eur J Clin Pharmacol, 2015, 71(7):817.

[29]王飞羽,江震,刘亦伟. GLP-1R基因多态性与2型糖尿病患者利拉鲁肽疗效的相关性研究[J].上海医药, 2021, 42(23):21.

[30]卢姗,李立,张朝云,等. GLP-1R rs6923761基因多态性和不同剂量利拉鲁肽对2型糖尿病伴肥胖/超重患者治疗效果和减重的影响[J].中南药学, 2021, 19(2):351.

[31] MASELLI D B, ATIEH J, KHANNA L, et al. 160 impact of gastric emptying and genetic variants related to glp-1 on weight loss with liraglutide in treatment of obesity:a 16-week, singlecenter, randomized, placebo-controlled trial in 76 patients[J].Gastroenterology, 2021, 160(6):S.

[32] MASELLI D, ATIEH J, CLARK M M, et al. Effects of liraglutide on gastrointestinal functions and weight in obesity:a randomized clinical and pharmacogenomic trial[J]. Obesity, 2022, 30(8):1608.

[33]任丽君,高红红,宋瑞捧.胰高血糖素样肽1受体基因遗传变异对利拉鲁肽治疗2型糖尿病患者疗效的影响[J].实用医学杂志,2023, 39(2):164.

[34] EGHBALI M, ALAEI-SHAHMIRI F, HASHEMI-MADANI N, et al. Glucagon-like Peptide1(GLP-1)receptor variants and glycemic response to liraglutide:a pharmacogenetics study in Iranian people with Type2 diabetes mellitus[J]. Adv Ther, 2024, 41(2):826.

[35] DE LUIS D A, OVALLE H F, SOTO G D, et al. Role of genetic variation in the cannabinoid receptor gene(CNR1)(G1359A polymorphism)on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2[J]. J Investig Med, 2014, 62(2):324.

[36]赵倩,杨广,曹莉华,等. CNR1基因遗传变异对利拉鲁肽治疗早期2型糖尿病患者临床疗效的影响[J].中国临床药理学与治疗学, 2020, 25(2):182.

[37]杨晓旭,赵振宇. CNR1基因rs1049353位点多态性与早期2型糖尿病患者利拉鲁肽疗效的关系[J].山东医药, 2021, 61(4):15.

[38]高红红,任丽君,马豪莉,等. SIRT1基因多态性对血糖控制不佳的2型糖尿病患者接受利拉鲁肽联合二甲双胍治疗效果的影响[J].实用医学杂志, 2021, 37(2):205.

[39]王春玲,周仁精,冯瑞,等.脂联素45T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J].中国临床药理学与治疗学, 2021, 26(3):312.

[40] KYRIAKIDOU A, KYRIAZOU A V, KOUFAKIS T, et al. Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes[J]. J Pers Med, 2022, 12(3):424.

[41] DORIS J M, MILLAR S A, IDRIS I, et al. Genetic polymorphisms of the endocannabinoid system in obesity and diabetes[J].Diabetes Obes Metab, 2019, 21(2):382.

[42] ARMSTRONG M J, GAUNT P, AITHAL G P, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis(LEAN):a multicentre, double-blind, randomised, placebocontrolled phase 2 study[J]. Lancet, 2016, 387(10019):679.

[43] NEWSOME P N, BUCHHOLTZ K, CUSI K, et al. A placebocontrolled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12):1113.

[44] URIAS E, TEDESCO N R, OLIVERI A, et al. PNPLA3 risk allele association with ALT response to semaglutide treatment[J].Gastroenterology, 2024, 166(3):515.

[45] KYRIAKIDOU A, KYRIAZOU A V, KOUFAKIS T, et al.Association between variants in TCF7L2, CTRB1/2, and GLP-1R genes and response to therapy with glucagon-like peptide-1receptor agonists[J]. Postgrad Med, 2024, 136(2):218.